Brief: Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

Kura Oncology

30/01/2024 12:25

Jan 30 (Reuters) - Kura Oncology Inc  KURA.O :
    * KURA ONCOLOGY REPORTS POSITIVE PRELIMINARY ZIFTOMENIB
COMBINATION DATA IN ACUTE MYELOID LEUKEMIA
    * KURA ONCOLOGY INC - 200 MG DOSE OF ZIFTOMENIB CLEARED IN
VEN/AZA
COHORTS, ENROLLMENT AT 400 MG DOSE ONGOING
    * KURA ONCOLOGY INC - 80% OF PATIENTS REMAIN ON TRIAL AS OF
DATA
CUTOFF, INCLUDING ALL NPM1-M PATIENTS
    * KURA ONCOLOGY INC - NO DIFFERENTIATION SYNDROME EVENTS OF
ANY
GRADE WERE REPORTED
    * KURA ONCOLOGY INC - REMAIN IN A STRONG FINANCIAL POSITION
WITH
CASH RUNWAY EXPECTED INTO 2027

Source text for Eikon:  ID:nGNXhDcqJ 
Further company coverage:  KURA.O 

 ((Reuters.Briefs@thomsonreuters.com;))